Exploring the In Vitro and In Vivo Therapeutic Potential of BRAF and MEK Inhibitor Combination in NRAS-Mutated Melanoma

Exploring the In Vitro and In Vivo Therapeutic Potential of BRAF and MEK Inhibitor Combination in NRAS-Mutated Melanoma

Introduction: Patients with NRAS-mutant metastatic melanoma often have an aggressive disease requiring a fast-acting, effective therapy. The MEK inhibitor binimetinib shows an overall response rate of 15% in patients with NRAS-mutant melanoma, providing a backbone for combination strategies. Our pre...

Full description

Bibliographic Details
Main Authors: Heike Niessner, Anna Hüsch, Corinna Kosnopfel, Matthias Meinhardt, Dana Westphal, Friedegund Meier, Bastian Schilling, Tobias Sinnberg
Format: Article
Language:English
Published: MDPI AG 2023-11-01
Series:Cancers
Subjects:
malignant melanoma
cancer
encorafenib
binimetinib
BRAF inhibitor
NRAS-mutated
Online Access:https://www.mdpi.com/2072-6694/15/23/5521

Internet

https://www.mdpi.com/2072-6694/15/23/5521

Similar Items